Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. 7 June 2019. Rebecca Parkes.

Executive Summary

Glooko, a leader in diabetes management data, and T1D Exchange, a nonprofit research group, have formed a collaborative agreement to use Glooko's platform to link anonymized diabetes device data from tens of thousands of type 1 diabetes patients with patients' electronic health-care records. See what T1D's Rebecca Parkes said about it here.

"We will be able to use these comprehensive data analytics to ultimately expand outcome measures for T1D [type 1 diabetes] and move beyond A1c [a blood test that reflects average blood glucose levels], informing our effort and mission to improve outcomes for people living with the disease." – Rebecca Parkes, interim chief operating officer, T1D Exchange

Click here for a free trial of Medtech Insight

 
Advertisement

Related Content

Glooko And T1D Exchange Enter Partnership To Leverage Device Data From Type 1 Diabetics

Topics

Advertisement
UsernamePublicRestriction

Register

MT125212

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel